Rheumatologists face challenges in protecting immunocompromised individuals, like those with herpes zoster infections. The recombinant zoster vaccine is safe and effective, but questions remain about its efficacy in immunocompromised populations, long-term protection, and identifying those at highest risk. Recent studies show the vaccine is effective in some immunocompromised groups, but ongoing research is needed. Patients on certain medications, like JAK inhibitors or glucocorticoids, are at higher risk. Recommendations for vaccine administration and addressing patient concerns, like potential disease flares, are crucial. Open communication between rheumatologists and patients can improve vaccine uptake and outcomes.
Source link
Making sense of zoster vaccination in the immunocompromised: ‘It’s all about treatment’
